One somewhat overlooked element of the Obama administration’s proposed federal budget is its desire to create the first regulatory process for government approval of so-called “follow-on biologics,” or generic versions of drugs manufactured by living organisms. These medicines are often used in treatments such as cancer, anemia, psoriasis and rare diseases, where little room for error exists.
Read More